Inactive Instrument

Nichi-Iko Pharmaceutical Co., Ltd.

4541

JP3687200000

Nichi-Iko Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022

May 17, 2021 at 10:00 pm EDT

Nichi-Iko Pharmaceutical Co., Ltd. provides earnings guidance for the fiscal year ending March 31, 2022. For the fiscal year ending March 31, 2022, the company will aim to achieve sales revenue of JPY 195 billion and core operating profit of JPY 2.5 billion.

Latest news about Nichi-Iko Pharmaceutical Co., Ltd.

Nakakita Yakuhin Co., ltd. acquired Yakuhan Pharmaceutical Co., Ltd. from Nichi-Iko Pharmaceutical Co., Ltd.	23-07-31	CI
Nichi-Iko Pharmaceutical Co., Ltd.(TSE:4541) dropped from S&P Global BMI Index	23-03-20	CI
Japan Shares End Flat on Last Trading Day of 2022; Nichi-Iko Pharmaceutical Shares Plummet 24%	22-12-30	MT
Nichi-Iko Pharmaceutical Secures 98.5 Billion Yen of Debt Relief, Plans 20 Billion Yen Share Allotment; Shares Plunge 20%	22-12-29	MT
Nichi-Iko Pharmaceutical More Than Triples Fiscal H1 Profit	22-12-12	MT
Nichi-Iko Pharmaceutical Co., Ltd. announced that it expects to receive Ã‘19.998404811 billion in funding from Godo Kaisha JSD	22-11-13	CI
Japan Index Trades Steadily in Red; Round One Shares Gain 9% as May Sales Exceed Pre-Pandemic Level	22-06-10	MT
Chugai Appeals Tokyo Court's Dismissal of Patent Infringement Lawsuit Against Sawai, Nichi-iko Pharmaceutical	22-06-10	MT
Court Denies Chugai's Claim in Lawsuit Against Sawai, Nichi-iko	22-05-30	MT
Nichi-Iko Pharmaceutical's Nine-Month Profit Soars	22-03-10	MT
Nichi-Iko Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022	22-03-09	CI
Court Denies Chugai's Claim in Lawsuit Against Sawai, Nichi-iko and Nissan Chemical	22-02-25	MT
Nichi-Iko Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022	21-12-03	CI
Nichi-Iko Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2021	21-09-06	CI
Nichi-Iko Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter and Full Year of Fiscal Ending March 31, 2022	21-09-06	CI
Nichi-Iko Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal Year Ending March 31, 2022	21-09-06	CI
Nichi-Iko Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022	21-09-06	CI
Nichi-Iko Pharmaceutical Co., Ltd. announced that it has received ¥5.23102 billion in funding from MediPal Holdings Corporation	21-09-01	CI
Nichi-Iko Pharmaceutical Co., Ltd. announced that it expects to receive ¥5.23102 billion in funding from MediPal Holdings Corporation	21-08-16	CI
Fuji Chemical Industries Co., Ltd. agreed to acquire Toyama No. 2 Factory of Nichi-Iko in Namerikawa City, Toyama Prefecture from Nichi-Iko Pharmaceutical Co., Ltd..	21-06-28	CI
Nichi-Iko Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year-End of Fiscal Year Ending March 31, 2022	21-06-14	CI
Nichi-Iko Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the Year Ended March 31, 2021	21-05-17	CI
Nichi-Iko Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022	21-05-17	CI
Nichi-Iko Pharmaceutical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2021, Payable on June 21, 2021; Provides Dividend Guidance for the Second Quarter of Fiscal Year Ending March 31, 2022	21-05-17	CI
Nichi-Iko Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022	21-05-13	CI

Chart Nichi-Iko Pharmaceutical Co., Ltd.

Duration

Period

Chart Nichi-Iko Pharmaceutical Co., Ltd.

More charts

Company Profile

Nichi-Iko Pharmaceutical Co.,Ltd. is a Japan-based company principally engaged in the manufacture and sale of generic pharmaceutical products and other medical products. The Company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription issued by a doctor in a hospitals or clinics, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed.

Sector

Pharmaceuticals

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B
SUPERNUS PHARMACEUTICALS, INC.	+3.90%	1.65B

Specialty & Advanced Pharmaceuticals